Download Full eBooks in PDF
Medicare Payments For Currently Covered Prescription Drugs Book in PDF, ePub and Kindle version is available to download in english. Read online anytime anywhere directly from your device. Click on the download button below to get a free pdf file of Medicare Payments For Currently Covered Prescription Drugs book. This book definitely worth reading, it is an incredibly well-written.
Author : United States. Congress. House. Committee on Ways and Means. Subcommittee on Health
Publisher : Unknown
Page : 102 pages
File Size : 46,9 Mb
Release : 2003
Category : Business & Economics
ISBN : STANFORD:36105050296735
Author : Anonim
Publisher : Unknown
Page : 60 pages
File Size : 43,6 Mb
Release : 2024-07-03
Category : Health insurance
ISBN : UOM:39015022573201
Author : Institute of Medicine,Board on Health Sciences Policy,Committee on Accelerating Rare Diseases Research and Orphan Product Development
Publisher : National Academies Press
Page : 442 pages
File Size : 43,8 Mb
Release : 2011-04-03
Category : Medical
ISBN : 9780309158060
Rare diseases collectively affect millions of Americans of all ages, but developing drugs and medical devices to prevent, diagnose, and treat these conditions is challenging. The Institute of Medicine (IOM) recommends implementing an integrated national strategy to promote rare diseases research and product development.
Author : National Academies of Sciences, Engineering, and Medicine,Health and Medicine Division,Board on Health Care Services,Committee on Ensuring Patient Access to Affordable Drug Therapies
Publisher : National Academies Press
Page : 235 pages
File Size : 54,6 Mb
Release : 2018-03-01
Category : Medical
ISBN : 9780309468084
Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
Author : Institute of Medicine,Committee on Routine Patient Care Costs in Clinical Trials for Medicare Beneficiaries
Publisher : National Academies Press
Page : 86 pages
File Size : 41,7 Mb
Release : 2000-03-17
Category : Medical
ISBN : 9780309068888
Increasingly over the past five years, uncertainty about reimbursement for routine patient care has been suspected as contributing to problems enrolling people in clinical trials. Clinical trial investigators cannot guarantee that Medicare will pay for the care required, and they must disclose this uncertainty to potential participants during the informed consent process. Since Medicare does not routinely "preauthorize" care (as do many commercial insurers) the uncertainty cannot be dispelled in advance. Thus, patients considering whether to enter trials must assume that they may have to pay bills that Medicare rejects simply because they have enrolled in the trial. This report recommends an explicit policy for reimbursement of routine patient care costs in clinical trials. It further recommends that HCFA provide additional support for selected clinical trials, and that the government support the establishment of a national clinical trials registry. These policies (1) should assure that beneficiaries would not be denied coverage merely because they have volunteered to participate in a clinical trial; and (2) would not impose excessive administrative burdens on HCFA, its fiscal intermediaries and carriers, or investigators, providers, or participants in clinical trials. Explicit rules would have the added benefit of increasing the uniformity of reimbursement decisions made by Medicare fiscal intermediaries and carriers in different parts of the country. Greater uniformity would, in turn, decrease the uncertainty about reimbursement when providers and patients embark on a clinical trial.
Author : Anonim
Publisher : Unknown
Page : 234 pages
File Size : 45,6 Mb
Release : 2000
Category : Drugs
ISBN : STANFORD:36105028431273
On October 25,1999, the President directed the Secretary of Health and Human Services to study prescription drug costs and trends for Medicare beneficiaries. He asked that the study investigate: price differences for the most commonly used drugs for people with and without coverage; drug spending by people of various ages, as a percentage of income and of total health spending; and trends in drug expenditures by people of different ages, as a percentage of income and of total health spending. This report is the Department's response to that request. It represents the work of individuals and agencies throughout the Department, including the Agency for Healthcare Research and Quality (AHRQ), the Food and Drug Administration (FDA), the Health Care Financing Administration (HCFA), and the Office of the Assistant Secretary for Planning and Evaluation (ASPE).
Author : United States. Health Care Financing Administration
Publisher : Unknown
Page : 6 pages
File Size : 51,7 Mb
Release : 1993
Category : Hospice care
ISBN : MINN:31951D01035074B
Author : United States. Congressional Budget Office
Publisher : Unknown
Page : 380 pages
File Size : 43,5 Mb
Release : 1977
Category : Budget
ISBN : MSU:31293017886775
Author : United States. Congress. Senate. Committee on Finance. Subcommittee on Health Care
Publisher : Unknown
Page : 100 pages
File Size : 47,6 Mb
Release : 2002
Category : Medical
ISBN : PURD:32754074745344
Author : Institute of Medicine,Division of Health Care Services,VA Pharmacy Formulary Analysis Committee
Publisher : National Academies Press
Page : 280 pages
File Size : 44,8 Mb
Release : 2000-10-03
Category : Medical
ISBN : 9780309183536
The VA National Formulary generated controversy, which motivated congressional scrutiny and a directive to the VA to commission this report reviewing the experience with the National Formulary and formulary system. This Institute of Medicine committee was pleased to assist the Congress with this review, in part because the committee saw in the VHA example an opportunity to understand and anticipate problems that all publicly funded programs are likely to encounter in this new age of pharmaceuticals. The Congress asked the committee to review the restrictiveness of the National Formulary, its impact on the costs and quality of care in the VHA, and how it compared to formularies and drug management practices in the private sector and in other public programs, especially Medicaid. Detailed in the pages that follow, the committee's findings and conclusions on these questions are, the committee believes, highly instructive, though not always in the ways that we anticipated.
Author : Sheila Shulman,Elaine M Healy
Publisher : CRC Press
Page : 216 pages
File Size : 50,6 Mb
Release : 1998-06-18
Category : Medical
ISBN : 0789005123
PBMs: Reshaping the Pharmaceutical Distribution Network provides HMOs and other third-party payers with information on the new and increasingly important role of pharmaceutical benefit companies (PBMs) in the health care industry. From this text, you will learn how PBMs can maintain and deliver a quality, cost-effective drug benefit plan to your company while achieving the anticipated market share for the product. PBMs: Reshaping the Pharmaceutical Distribution Network offers you suggestions on how to choose which PBM service is correct for your business, such as what qualifications to look for in a PBM, as well as what questions you should ask a respective company. This text also offers ways on how your company can benefit from becoming a client and may make your business more competitive in the pharmaceutical industry. PBMs: Reshaping the Pharmaceutical Distribution Network also informs you about the controversies that have arisen concerning the new position of PBMs in the industry. Through research and evaluation, this text addresses these issues from many different perspectives and gives you insight into other topics concerning PBMs, including: operating methods that PBMs currently rely on for designing and overseeing a drug benefit plan how the Food and Drug Administration currently views the role of PBMs and why they are contemplating regulatory intervention alerting PBMs, pharmacies, pharmaceutical companies, and managed care organizations to new legal issues involving fraud and abuse affecting pharmacy benefit management and pharmaceutical manufacturers reasons why retail drug chains and pharmacist organizations oppose recent industry developments regarding PBMs whether or not PBMs reflect a move toward greater centralized decisionmaking in the health care systemIn addition, PBMs: Reshaping the Pharmaceutical Distribution Network offers pharmaceutical companies, health care providers, and managed care organizations several suggestions for further research, which may make your business or your business relationships more efficient and productive in the future. If you or your company are considering the services of a pharmacy benefit management, PBMs: Reshaping the Pharmaceutical Distribution Network will guide you in choosing a company that helps you deliver the most cost-effective and efficient pharmaceutical benefits to customers.
Author : United States. Congress
Publisher : Unknown
Page : 850 pages
File Size : 47,6 Mb
Release : 2003
Category : Electronic government information
ISBN : PURD:32754077083461
Author : Anonim
Publisher : Unknown
Page : 20 pages
File Size : 54,6 Mb
Release : 1990
Category : Income tax deductions for medical expenses
ISBN : MINN:30000001753056
Author : Patricia Barry
Publisher : John Wiley & Sons
Page : 386 pages
File Size : 52,6 Mb
Release : 2008-09-29
Category : Business & Economics
ISBN : 9780470276761
Confused about Medicare’s drug coverage? You’re not alone. Medicare Prescription Drug Coverage For Dummies explains Part D in plain English and shows you how to find the best deal among numerous drug-coverage plan options. Whether you’re new to Medicare or already in the program, you’ll navigate the system with more ease and confidence, avoid pitfalls and scams, and have plenty of help choosing the plan that’s right for you. This easy-to-understand, consumer-friendly guide helps you find out whether Part D affects any drug coverage you already have and weigh the consequences of going without coverage. You’ll find ways to compare plans, identify the one that covers your drugs at the least cost, and make sure you sign up at the right time. And you’ll learn how to minimize your expenses, use the “right” pharmacies, and troubleshoot any problems with your coverage. Discover how to: Decide whether you need Part D Understand how Part D works, from costs to coverage Choose and enroll in the best plan for you Get up and running with Part D Handle the coverage gap Lower your drug costs Join and switch plans Comply with long-term-care rules and rights Challenge plan decisions Avoid scams and hard-sell marketing Now, more than ever, you need clear, reliable information that helps you understand Part D and make smart, cost-saving healthcare decisions. You need Medicare Prescription Drug Coverage For Dummies.
Author : United States. Congress. House. Committee on Energy and Commerce
Publisher : Unknown
Page : 300 pages
File Size : 55,6 Mb
Release : 2003
Category : Government publications
ISBN : UCR:31210017997576